课题基金 / 基金详情

AMBISOME VS AMPHOTERICIN B AND FLUCONAZOLE IN CRYPTOCOCCAL MENINGITIS IN AIDS

AMBISOME VS AMPHOTERICIN B AND FLUCONAZOLE IN CRYPTOCOCCAL MENINGITIS IN AIDS
Ambisome 对比两性霉素 B 和氟康唑治疗艾滋病隐球菌性脑膜炎
批准号：
6121097
负责人：
PHILIP C JOHNSON
金额：
$1.51万
依托单位：
UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON
依托单位国家：
美国
项目类别：
财政年份：
1998
资助国家：
美国
项目状态：
已结题
起止时间：
1998-12-01 至 1999-11-30
来源：
https://reporter.nih.gov/project-details/6121097
关键词：
AIDS AIDS therapy Cryptococcus amphotericin B bacterial meningitis clinical research combination chemotherapy drug screening /evaluation fluconazole human subject human therapy evaluation microorganism disease chemotherapy opportunistic infections

项目摘要

项目成果

PHILIP C JOHNSON的其他基金

相似基金

相关文献

中文摘要
翻译
这是一项第三阶段的随机、双盲、多中心研究，旨在评估两种剂量的AmBisome(脂质体两性霉素B)与两性霉素B以及随后的氟康唑治疗艾滋病患者首次发作的急性隐球菌性脑膜炎的安全性、耐受性和有效性。患者将接受AmBisome或两性霉素B IV治疗2周，然后是8周的氟康唑。主要疗效结果是在可评估的亚组中评估的治疗成功的发生率。这项研究最近完成，目前正在进行分析。
英文摘要
This is a Phase III randomized, double-blind, multicenter study designed to evaluate the safety, tolerability and efficacy of two doses of AmBisome (Lipo-somal amphotericin B) versus amphotericin B, followed by fluconazole, for a first episode of acute cryptococcal meningitis in patients with AIDS. The patient will receive AmBisome or amphotericin B IV for 2 weeks, followed by eight weeks of fluconazole. The primary efficacy outcome is the incidence rate of the therapeutic success assessed in the evaluable subgroup. This study was recently completed and is being analyzed.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
COMPARISON OF ANTIRETROVIRAL ACTIVITY OF 3 COMBINATION REGIMENS IN HIV+ PATIENTS
AMBISOME COMPARED WITH AMPHOTERICIN B FOR HISTOPLASMOSIS IN AIDS PTS
COMPARISON OF ANTIRETROVIRAL ACTIVITY OF 3 COMBINATION REGIMENS IN HIV+ PATIENTS
COMBINATION TRIAL OF DLV, ZDV AND 3TC AS INITIAL OR FOLLOWUP THERAPY (PART II)
海外基金